[Correspondence] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer

We read with great interest the ADJUVANT study,1 the first prospective phase 3 study showing longer disease-free survival for adjuvant tyrosine-kinase inhibitor (TKI) treatment than for cisplatin-based chemotherapy in patients with completely resected stage II –IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer (NSCLC). However, some important issues remain.

Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Fang Wu, Xianling Liu, Jin-an Ma, Yawen Gao, Chunhong Hu Tags: Correspondence Source Type: research